Home HOME General Physiology and Biophysics 2022 General Physiology and Biophysics Vol.41, No.1, p. 1–14, 2022

Journal info


Founded: 1982
ISSN 1338-4325 (online)
ISSN 0231-5882 (print)
Published in English,
6 times per year

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

General Physiology and Biophysics Vol.41, No.1, p. 1–14, 2022

Title: Advances in studies of ncRNAs in the pathophysiology and treatment of spinal disease
Author: Jie Wang, Wei Wei, Youji Jia, Xiaobing Xi, Ying Jin
Abstract: Symptoms of spinal disease frequently accompany altered or damaged spine and vertebral structures resulting from endogenous and exogenous factors. Back braces, therapeutic agents, and surgery remain the main treatments for spinal diseases. However, the efficacy of currently available therapeutic agents is limited due to their side effects, whereas back braces and surgeries are less effective for certain patients. The significant effect of spinal disease on patients’ morbidity and mortality emphasizes the necessity to develop novel and more effective therapeutic agents that mitigate the consequences of spinal disease. Accumulating research acknowledges that non-coding RNAs (ncRNAs), including miRNAs, lncRNAs, circRNAs, etc., are involved in the pathogenesis of spinal disease, their pronounced therapeutic potential and significant regulatory functions in spinal diseases. Hence, this review focuses on summarizing the latest advances in studies of ncRNAs in the progression and recovery of spinal diseases, as well as highlighting the collaboration of ncRNA networks in treating spinal disease.
Keywords: Symptoms of spinal disease frequently accompany altered or damaged spine and vertebral structures resulting from endogenous and exogenous factors. Back braces, therapeutic agents, and surgery remain the main treatments for spinal diseases. However, the efficacy of currently available therapeutic agents is limited due to their side effects, whereas back braces and surgeries are less effective for certain patients. The significant effect of spinal disease on patients’ morbidity and mortality emphasizes the necessity to develop novel and more effective therapeutic agents that mitigate the consequences of spinal disease. Accumulating research acknowledges that non-coding RNAs (ncRNAs), including miRNAs, lncRNAs, circRNAs, etc., are involved in the pathogenesis of spinal disease, their pronounced therapeutic potential and significant regulatory functions in spinal diseases. Hence, this review focuses on summarizing the latest advances in studies of ncRNAs in the progression and recovery of spinal diseases, as well as highlighting the collaboration of ncRNA networks in treating spinal disease.
Published online: 14-Feb-2022
Year: 2022, Volume: 41, Issue: 1 Page From: 1, Page To: 14
doi:10.4149/gpb_2021039


download file


© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.